AGIO - Agios Pharmaceuticals Stock Trading

Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which biotechnology treatment, device or therapy will give the biggest return, which makes biotechnology exchange-tr...

Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million CAMBRIDGE, Mass.,...

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinic...